FDA Added Boxed Warning to Adzynma Therapy
Patients and providers should monitor for antibodies that can block this congenital TTP treatment.
Updated on Sept. 23, 2026 in Allergies
The FDA has mandated a new Boxed Warning for the enzyme replacement therapy Adzynma after reports that some patients developed neutralizing antibodies. These antibodies can prevent the medication from working, a risk that was identified in recent safety monitoring.
Why it matters
This warning alerts clinicians and patients to the risk of treatment failure caused by immune system responses to the therapy. Ensuring patients are monitored for these antibodies is critical for maintaining effective management of congenital thrombotic thrombocytopenic purpura.
A safety signal identified via the FDA Adverse Event Reporting System documented the emergence of neutralizing antibodies in patients, including a fatal case in a 7-year-old child 10 months after starting treatment. The extent of this immune response across the entire patient population remains under investigation.
The players
Takeda Pharmaceuticals
The manufacturer of Adzynma, specializing in rare disease treatments and plasma-derived therapies.
FDA
The United States federal agency responsible for regulating pharmaceuticals and blood-derived biologics to ensure patient safety.
The details
Adzynma is a recombinant ADAMTS13 enzyme replacement therapy designed to address the underlying deficiency in patients with congenital thrombotic thrombocytopenic purpura. When a patient's immune system recognizes the therapy as a foreign substance, it may produce neutralizing antibodies that effectively bind to the drug. This interaction inhibits the enzyme's function, rendering the treatment ineffective and potentially leading to severe health complications.
Timeline
November 9, 2023: The FDA approved Adzynma for use.
September 23, 2026: The FDA issued a new Boxed Warning requirement.
Health Landscape
This mandate follows established regulatory precedents for flagging serious, treatment-limiting safety risks in biological therapies. The update underscores the ongoing challenge of managing immunogenicity in enzyme replacement protocols for rare conditions.
Patients receiving Adzynma should undergo regular laboratory testing to monitor for the presence of neutralizing antibodies. Discuss these testing protocols and any history of allergic reactions with your physician to ensure your treatment plan remains safe and effective.
The takeaway
The development of neutralizing antibodies can limit the efficacy of enzyme replacement therapy in some patients. If you are currently on this treatment, ask your doctor about the recommended frequency for monitoring antibodies and report any unexpected symptoms during your next visit.
Further reading
For more context on managing severe immune sensitivities and related treatments, visit Allergies.
More information
Review the official FDA safety communication and labeling updates for full details.
Source note: This article includes information reported by U.S. Food and Drug Administration.
